Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 5/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CDC7 | O00311 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9952459 | 0.91 | NOTUM (0.45) | STIM1ORAI1NPC1CASP3RAB9A | |
| SCHEMBL9953228 | 0.89 | NPC1 (0.39) | STIM1ORAI1NPC1CASP3RAB9A | |
| SCHEMBL9952540 | 0.88 | KDM4E (0.45) | STIM1ORAI1NPC1CASP3RAB9A | |
| SCHEMBL10194777 | 0.85 | LRRK2 (0.43) | NPC1RAB9AITKALDH1A1CHEK1 | |
| SCHEMBL17850404 | 0.82 | ITK (0.45) | NPC1CASP3RAB9ASENP8SENP7 | |
| SCHEMBL9951937 | 0.80 | MAP2K4 (0.61) | STIM1ORAI1MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL10194985 | 0.77 | HTR2C (0.42) | PIM1ITKMIFGRM4FGFR1 | |
| SCHEMBL9951780 | 0.75 | GRM4 (0.45) | RAB9AMAP2K4MAPK1MAPKAPK3MAPK6 | |
| SCHEMBL9952065 | 0.74 | CDC7 (0.46) | MAP2K4MAPK1MAPKAPK3MAPK6CDK2 | |
| SCHEMBL27945220 | 0.74 | MAP2K4 (0.47) | MAP2K4MAPK1MAPKAPK3MAPK6CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| CN-103429585-A | Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors | MERCK SERONO SA | 2013-12-04 | — | — | CN | disclosed |
| EP-2655357-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | Merck Serono S.A. (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | STIM1 1679/4885ORAI1 3585/4885NPC1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.